Literature DB >> 15807181

Silent myocardial ischemia and high-grade ventricular arrhythmias in patients on maintenance hemodialysis.

Khalid Mohi-ud-din1, Harinder K Bali, Sunip Banerjee, Vinay Sakhuja, Vivekanand Jha.   

Abstract

The occurrence of silent myocardial ischemia (SMI) and serious arrhythmias during hemodialysis (HD) has been well documented. However, it is unclear whether these changes are due to epicardial coronary artery disease (CAD). We conducted a prospective study to assess whether SMI and arrhythmias during HD correlated with angiographically demonstrable CAD. Twenty-three patients with end-stage renal disease on maintenance HD underwent 48-hour Holter monitoring, beginning 24 hours prior to a HD session. All patients underwent biochemical evaluation, coronary angiography, and echocardiography. Holter monitoring showed SMI during HD in 22% cases. A significant increase in the frequency of ventricular ectopics (VEs) was noted during and after HD. Patients who showed SMI during HD and VEs prior to initiation of dialysis were more likely to develop significant ventricular arrhythmias during and after HD. Epicardial CAD was documented in four patients, and it did not correlate with SMI. To conclude, HD is an arrhythmogenic process. SMI during dialysis is probably not due to epicardial CAD but predisposes to clinically significant ventricular arrhythmias during and after HD. The cause of SMI during HD in patients without demonstrable CAD needs further investigation.

Entities:  

Mesh:

Year:  2005        PMID: 15807181

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  8 in total

1.  What Is the Meaning of Increased Myocardial Injury Enzymes during Hemodialysis? A Tissue Doppler Imaging Study.

Authors:  Gürsel Yildiz; Mansur Kayataş; Ferhan Candan; Mehmet Birhan Yilmaz; Ali Zorlu; Savaş Sarikaya
Journal:  Cardiorenal Med       Date:  2013-06-25       Impact factor: 2.041

2.  2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry.

Authors:  Jonathan S Steinberg; Niraj Varma; Iwona Cygankiewicz; Peter Aziz; Paweł Balsam; Adrian Baranchuk; Daniel J Cantillon; Polychronis Dilaveris; Sergio J Dubner; Nabil El-Sherif; Jaroslaw Krol; Malgorzata Kurpesa; Maria Teresa La Rovere; Suave S Lobodzinski; Emanuela T Locati; Suneet Mittal; Brian Olshansky; Ewa Piotrowicz; Leslie Saxon; Peter H Stone; Larisa Tereshchenko; Mintu P Turakhia; Gioia Turitto; Neil J Wimmer; Richard L Verrier; Wojciech Zareba; Ryszard Piotrowicz
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05       Impact factor: 1.468

Review 3.  Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations.

Authors:  Srisakul Chirakarnjanakorn; Sankar D Navaneethan; Gary S Francis; W H Wilson Tang
Journal:  Int J Cardiol       Date:  2017-01-04       Impact factor: 4.164

4.  Painless myocardial ischemia is associated with mortality in patients with chronic kidney disease.

Authors:  James B Wetmore; Mike Broce; Amer Malas; Ammar Almehmi
Journal:  Nephron Clin Pract       Date:  2013-03-01

5.  Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle.

Authors:  Mariantonietta Cicoira; Stefan D Anker; Claudio Ronco
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-08-24       Impact factor: 12.910

6.  Association between troponin I level and cardiovascular risk factors in asymptomatic hemodialysis patients.

Authors:  Shahram Taheri; Ali Asghar Pilehvarian; Nafiseh Akbari; Samane Musavi; Afsoon Emami Naeini
Journal:  J Res Pharm Pract       Date:  2016 Apr-Jun

7.  Intravital microscopic observation of the microvasculature during hemodialysis in healthy rats.

Authors:  B G H Janssen; Y M Zhang; I Kosik; A Akbari; C W McIntyre
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

8.  Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient.

Authors:  Mozow Y Zuidema; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2012-03-30       Impact factor: 2.041

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.